Madison-based Exact Sciences reduced its second-quarter loss compared to a year ago and beat analysts’ expectations in results announced Tuesday.
The biomedical giant best known for its Cologuard test reported a second-quarter net loss of $166.1 million, or $0.94 per share, on revenue $521.6 million, compared to a net loss of $176.9 million, or $1.03 per share, on revenue of $434.8 million for the same period a year ago.
The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.07 per share on revenue of $496.8 million, the Associated Press reported.
;
